)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Dianthus Therapeutics (DNTH) investor relations material
Dianthus Therapeutics Corporate Presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate Presentation summary2 Dec, 2025
Strategic focus and pipeline overview
Advancing two autoimmune therapeutics, claseprubart and DNTH212, each with best-in-class, pipeline-in-a-product potential targeting infrequent, patient-friendly self-administration.
Claseprubart is a potent classical pathway inhibitor with clinical proof-of-concept in gMG, CIDP, and MMN, aiming for convenient subcutaneous dosing every 2 or 4 weeks.
DNTH212 is a bifunctional BDCA2 and BAFF/APRIL inhibitor, showing superior in vitro efficacy and targeting both innate and adaptive immune systems.
Strong financial position with ~$525M in cash, providing runway into 2028 to fund multiple near-term catalysts.
Key upcoming milestones include multiple Phase 3 and Phase 2 trial initiations and readouts for both assets through 2026.
Claseprubart clinical data and market opportunity
Phase 2 MaGic trial in gMG showed rapid, sustained, and statistically significant improvements in MG-ADL, QMG, MGC, and MG-QOL-15r scores versus placebo.
Over 60% of patients on 300mg/2mL achieved ≥5-point improvement in MG-ADL and QMG; 37% achieved minimal symptom expression at week 13.
Safety profile was favorable, with no serious infection signals, no autoimmune activation, and no boxed warning or REMS anticipated.
Targeting a large, underpenetrated U.S. gMG market (>100,000 patients), with <20% currently treated with biologics and a market size >$3.5B.
Phase 3 trial to include Q4W dosing and refined screening criteria, aiming to further differentiate on efficacy and convenience.
Expansion into CIDP and MMN
CIDP market (>40,000 U.S. patients) has high unmet need; active C1s inhibition validated by riliprubart, but claseprubart offers superior potency and more convenient dosing.
Phase 3 CAPTIVATE trial in CIDP includes open-label and randomized withdrawal design, with interim responder analysis expected in Q2'26.
MMN market (~10,000 U.S. patients) is underdiagnosed; classical pathway inhibition validated, and claseprubart aims to become new standard of care with low-volume, self-administered dosing.
Phase 2 MOMENTUM trial in MMN is ongoing, with top-line data expected in 2H'26.
Ph3 gMG: QMG >10 screen & Q4W dosing impact
DNTH212: Bifunctional efficacy advantage
Claseprubart: Lectin pathway preservation
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Dianthus Therapeutics earnings date
Q4 202511 Mar, 2026
Next Dianthus Therapeutics earnings date
Q4 202511 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Dianthus Therapeutics Inc., operating under the ticker DNTH, is a clinical-stage biotechnology company based in New York, New York. The company focuses on designing, developing, and delivering innovative monoclonal antibodies intended for the treatment of severe autoimmune and inflammatory diseases. Their key developmental product is DNTH103, currently in clinical trials, targeted at conditions such as generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. The company is headquartered in New York, NY, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage